Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Perspectives
Open Access

How COVID-19 Has Changed the Management of Glomerular Diseases

Andrew S. Bomback, Pietro A. Canetta, Wooin Ahn, Syeda B. Ahmad, Jai Radhakrishnan and Gerald B. Appel
CJASN June 2020, 15 (6) 876-879; DOI: https://doi.org/10.2215/CJN.04530420
Andrew S. Bomback
The Center for Glomerular Diseases, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pietro A. Canetta
The Center for Glomerular Diseases, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pietro A. Canetta
Wooin Ahn
The Center for Glomerular Diseases, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wooin Ahn
Syeda B. Ahmad
The Center for Glomerular Diseases, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jai Radhakrishnan
The Center for Glomerular Diseases, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald B. Appel
The Center for Glomerular Diseases, Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York City, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • glomerular disease
  • immunosuppression
  • COVID-19
  • severe acute respiratory syndrome coronavirus 2
  • kidney diseases

A 26-year-old woman contacted our office asking for an urgent call back. She had a history of steroid-dependent and frequently relapsing minimal change disease, and calls like this usually meant her home dipsticks had turned positive. Instead, she reported that she had just tested positive for the 2019 novel coronavirus (SARS-CoV-2 or COVID-19). She had a low-grade fever, myalgias, and a reduced sense of smell, but fortunately no cough or shortness of breath. She was worried about her dipsticks, however, which were still negative. What was usually a reassuring do-it-yourself test now frightened her. “Does that mean the rituximab is still in my system?” she asked, referring to the infusion she had done about 4 months earlier.

As COVID-19 infections spread across the world, nephrologists and their patients face difficult decisions regarding management of glomerular diseases. Our Center for Glomerular Diseases has fielded countless questions in the last few weeks, not just from patients but from other nephrologists about the most appropriate way to handle immunosuppression in the current climate. Should lupus nephritis patients reduce their mycophenolate mofetil doses or stop the drug altogether? Should membranous nephropathy patients with rising titers of antibodies to the phospholipase A2 receptor (PLA2R) proceed with their scheduled rituximab infusions? Should severe ANCA-associated GN patients in the midst of an intravenous course of cyclophosphamide switch over to oral cyclophosphamide to avoid trips into the infusion center? Of course, there are no perfect, or even evidence-based, answers to these and other inquiries. Here, we offer some insight as to how our center in New York City, currently the world’s hottest spot for COVID-19 infections, has adapted the management of our glomerular disease patients to reduce complications of potential COVID-19 disease (Table 1). We also speculate on how our practice will be altered in the future, even at a time when, hopefully, COVID-19 infections are a thing of the past.

View this table:
  • View inline
  • View popup
Table 1.

Concise guidelines for management of glomerular disease patients during the COVID-19 pandemic (opinion-based)

While considering the impact of immunosuppression on COVID-19 outcomes, nephrologists must simultaneously account for the potential impact on kidney outcomes from withholding immunosuppression. Therefore, we are still advising that patients who are at high risk of progression to ESKD without immediate therapy begin standard of care immunosuppression regimens. These patients are principally those with rapidly progressive glomerulonephritides due to lupus, ANCA, and anti–glomerular basement membrane-associated disease. In addition, patients with severe forms of nephrotic syndrome that are already manifesting reductions in kidney function, or complications related to proteinuria and hypoalbuminemia (e.g., deep venous thrombosis and anasarca), fit this criterion. In contrast, we have advised many of our patients who otherwise would be treated with immunosuppression to postpone treatment until their local transmission rates of COVID-19 are low enough that social distancing measures are no longer recommended. These include the following: (1) membranous nephropathy patients with nephrotic syndrome and/or rising anti-PLA2R antibody titers, but without complications and with preserved eGFR, (2) minimal change disease or FSGS patients with preserved eGFR, and (3) IgA nephropathy patients with endocapillary hypercellularity and/or low crescentic burden on kidney biopsy with preserved eGFR. In addition, for diseases without a validated standard of care regimen, such as immune complex or complement-mediated forms of membranoproliferative GN, we are not advocating immunosuppressive therapy at this time regardless of clinical parameters.

Glomerular disease patients who started immunosuppressive therapy prior to the COVID-19 pandemic require a risk-benefit assessment regarding continuation of immunosuppression, which should account for the potential impact of modifying or stopping treatment, as well as patient access to therapies. Patients in the midst of an intravenous induction regimen (e.g., EuroLupus dosing of intravenous cyclophosphamide for lupus nephritis) can be changed to an equivalent oral induction regimen if one exists (e.g., use of oral cyclophosphamide or high-dose mycophenolate mofetil for lupus nephritis) to potentiate stay-at-home adherence and avoid exposure to health care settings. Likewise, many patients who would receive pulse methylprednisolone intravenous treatments can be treated with high-dose oral prednisone or oral methylprednisolone. We have leveraged home infusion services to maintain necessary infusions while minimizing (without eliminating) social contact. Alterations to maintenance immunosuppression regimens should be individualized according to disease status and drug class. For example, stable patients on chronic immunosuppression should lower their doses to the safest level that will maintain remission; for many of our patients, this translates to a 50% drop in cumulative dose. If disease remission already extends >12 months, we consider immediate cessation of antimetabolites like mycophenolate mofetil or azathioprine, and we are not dosing maintenance rituximab infusions. Patients in sustained remission on maintenance steroids can, if on a low and alternate-day dose, discontinue these agents; otherwise, we begin a taper with dose adjustments every 2 weeks. We do not adjust the dose of calcineurin inhibitors in line with recommendations from our kidney transplant colleagues, who have recently reported that COVID-19–infected allograft recipients maintained on calcineurin inhibitors alone, with the antimetabolite held, have similar hospital-based outcomes compared with non–immune suppressed COVID-19–infected patients (1).

As many glomerular disease patients are young without significant comorbidities, suspected or confirmed cases of COVID-19 infection can often be managed at home without the need for hospitalization. For such patients, we recommend discontinuation of antimetabolites as part of their management and ask for continued communication on their clinical course with our office. Patients with glomerular diseases who require hospitalization for COVID-19 respiratory illnesses should, in addition to holding their antimetabolites, be started on stress doses of corticosteroids if on a long-term steroid regimen. If hydroxychloroquine and azithromycin are started on patients with nephrotic-range proteinuria, close monitoring of calcium levels is required, and it is mandatory to confirm that a baseline electrocardiogram has a normal QTc interval.

Our Center for Glomerular Diseases averages about 3000 annual office visits for glomerular disease care. Since mid-March 2020, we have moved the entirety of our clinic to telemedicine encounters using video visits. Telemedicine video visits with our physicians and support staff have been helpful to answer patients’ questions, allay their concerns, and maintain contact with them during home sequestration. Patients can monitor their BPs, daily weights, and symptoms of glomerular disease and relate these in real time to our staff. For example, peripheral edema can be easily visualized with cell phone and tablet cameras. Laboratory surveillance is a critical component of managing glomerular disease patients. We have limited this surveillance to primarily focus on safety laboratories that can be drawn at a commercial laboratory (i.e., not a hospital-based laboratory) that is enforcing social distancing among its clients. As an alternative, for some patients we have been able to use laboratory services that provide home testing visits. We have always relied on the use of urine dipsticks for home monitoring of disease status and include a review of dipstick results in our telemedicine visits. Importantly, if a patient contacts our office with symptoms suggestive of COVID-19 infection, such as cough, fever, and/or myalgias, a video visit potentiates better assessment of dyspnea and respiratory effort than a phone call for triaging whether the patient should be seen at an emergency room for oxygen therapy and potential hospital admission.

New enrollment into clinical trials has been paused during the COVID-19 crisis, but glomerular disease patients enrolled in therapeutic clinical trials that offer the prospect of direct benefit to participants should continue on the study drug. Many single-arm but also randomized clinical trials, particularly in phases 2 and 3, allow participants access to novel or unapproved therapies and thus have the prospect of benefit. The Food and Drug Administration has provided guidance (2) on conducting clinical trials during the pandemic, which includes sending study drugs to participants if oral or subcutaneous agents, or dosing study drugs in an outpatient infusion center with appropriate protocols for safe infusion therapy if an intravenous agent. The American College of Rheumatology has provided recommendations (3) for facilities providing infusion therapy during the COVID-19 crisis (Table 2). Visits that do not require study drug administration can be converted to telemedicine encounters. Study laboratories that are required for safety monitoring can be performed at commercial laboratories, at which time outcome-associated laboratories that are standard (e.g., creatinine and proteinuria) can also be collected. Some clinical trials have provided subjects with mailing kits for biosamples procured at local laboratories, so that these specimens can still be processed at a central study laboratory.

View this table:
  • View inline
  • View popup
Table 2.

Infusion suite strategies to reduce risk of COVID-19 infection (adapted from American College of Rheumatology guidance document)

Kidney biopsies fit the definition of “elective procedures,” which have been cancelled in many institutions at this time. We still are performing kidney biopsies in settings where we expect that findings are crucial for the immediate management of patients (e.g., rapidly progressive GN). Patients with apparent primary nephrotic syndrome and preserved eGFR should not undergo biopsies at this time; they can be managed empirically with calcineurin inhibitors with a biopsy to follow at a safer date. The use of anti-PLA2R antibody testing to diagnose primary membranous nephropathy can be helpful in this situation (4). Protocol biopsies to assess the efficacy of immunosuppression and activity versus chronicity of disease, as well as research biopsies for clinical trials or observational studies, should be cancelled.

As we reduce our glomerular disease patients’ exposure to immunosuppression, we often need to adjust our conservative therapies, particularly renin-angiotensin-aldosterone system blocking agents and diuretics. Despite recent controversies regarding the possible impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 transmission, we adhere to the recommendations made by experts across various disciplines (cardiology, nephrology, and hypertension) not to discontinue these drugs (5–⇓7). Therefore, we keep our patients on these agents and, if proteinuria is heavy in patients being weaned off immunosuppression, consider either increasing the dose of angiotensin-converting enzyme inhibitor or angiotensin receptor blockers or, alternatively, keeping the dose unchanged but adding a mineralocorticoid receptor blocker (e.g., eplerenone). For patients already on chronic hydroxychloroquine therapy, we are continuing the drug but not altering the dose; in the event of a drug shortage, we will need to consider dose reductions for these patients. We are not starting any patients on this drug prophylactically and are seeing cases of COVID-19 infection in lupus patients on maintenance hydroxychloroquine.

We anticipate that our management of glomerular disease patients will be altered by our current COVID-19–influenced practices even when the current pandemic has resolved. We have seen significantly lower rates of rapidly progressive GN in our hospitalized patients and disease relapses in our clinic patients since widespread adoption of social distancing. We have heard similar reports from our colleagues in other disciplines (e.g., fewer myocardial infarctions seen by cardiologists). This seemingly quiescent disease state supports the hypothesis that environmental exposures, including but not limited to infections, may be a major trigger of glomerular disease onset and relapse. While we do not foresee advocating formal social distancing for immunosuppressed patients outside of a pandemic window, we will repeatedly reinforce patient education on measures to reduce infectious exposures such as strict avoidance of sick contacts, frequent handwashing, avoiding touching of the face, and, whenever possible, staying at least 2 m away from other individuals. We also foresee wide adoption of telemedicine encounters to reduce time in healthcare settings for many of our glomerular disease patients, especially in follow-up visits when these patients are often on their highest doses of immunosuppressants.

Most importantly, given forecasts of a possible second wave of COVID-19 infections after the current pandemic has abated, as well as broader speculation that we are now firmly entrenched in an era of viral pandemics, we will need to consider the degree to which we are immunosuppressing all of our glomerular disease patients regardless of current infection rates. Fortunately, the field of glomerular diseases has been moving in this direction well before the emergence of COVID-19. For example, the Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis study showed noninferior outcomes in Anti-Neutrophil Cytoplasm Antibody-associated GN with a reduced dose of corticosteroids compared with a standard dose of corticosteroids (8), the Supportive versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy and Therapeutic Evaluation of Steroids in IgA Nephropathy Global trials argued against use of high dose corticosteroids for IgA nephropathy (9,10), and the Membranous Nephropathy Trial of Rituximab study found better long-term outcomes with just one or two dosing intervals of rituximab compared with year-long therapy with cyclosporine (11). But we likely will need to go even further than these trials and begin to question, for each glomerular disease, how much immunosuppression is needed to induce a remission and whether long-term maintenance therapy is required to sustain this remission. In other words, the debates on risks versus benefits of immunosuppression that we are forced to have now in the face of widespread COVID-19 infections should continue past this year, when our world, and our patients, will be very different because of what we are experiencing now.

Disclosures

Dr. Ahmad, Dr. Ahn, Dr. Appel, Dr. Bomback, Dr. Canetta, and Dr. Radhakrishnan have nothing to disclose.

Funding

Dr. Bomback and Dr. Canetta are supported, in part, by National Institutes of Health grant UM1DK100876.

Acknowledgments

The content of this article does not reflect the views or opinions of the American Society of Nephrology (ASN) or CJASN. Responsibility for the information and views expressed therein lies entirely with the authors.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. The Columbia University Kidney Transplant Program
    : Early description of coronavirus 2019 disease in kidney transplant recipients in New York. J Am Soc Nephrol 31: XXX–XXX, 2020
    OpenUrlPubMed
  2. ↵
    1. U.S. Food & Drug Administration
    : FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic. Available at: www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-pandemic. Accessed April 11, 2020
  3. ↵
    1. American College of Rheumatology
    : ACR infusion guidance during COVID-19 crisis. Available at: www.rheumatology.org/Portals/0/Files/ACR-Infusion-Guidance-COVID-19.pdf. Accessed April 11, 2020
  4. ↵
    1. Bobart SA,
    2. De Vriese AS,
    3. Pawar AS,
    4. Zand L,
    5. Sethi S,
    6. Giesen C,
    7. Lieske JC,
    8. Fervenza FC
    : Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies. Kidney Int 95: 429–438, 2019pmid:30665573
    OpenUrlCrossRefPubMed
  5. ↵
    1. Danser AHJ,
    2. Epstein M,
    3. Batlle D
    : Renin-angiotensin system blockers and the COVID-19 pandemic: At present there is no evidence to abandon renin-angiotensin system blockers [published online ahead of print Mar 25, 2020]. Hypertension doi:10.1161/HYPERTENSIONAHA.120.15082
    OpenUrlCrossRef
  6. ↵
    1. Sparks MA,
    2. South A,
    3. Welling P,
    4. Luther JM,
    5. Cohen J,
    6. Byrd JB,
    7. Burrell LM,
    8. Batlle D,
    9. Tomlinson L,
    10. Bhalla V,
    11. Rheault MN,
    12. Soler MJ,
    13. Swaminathan S,
    14. Hiremath S
    : Sound science before quick judgement regarding RAS blockade in COVID-19 [published online ahead of print Mar 27, 2020]. Clin J Am Soc Nephrol doi:10.2215/CJN.03530320
  7. ↵
    1. Vaduganathan M,
    2. Vardeny O,
    3. Michel T,
    4. McMurray JJV,
    5. Pfeffer MA,
    6. Solomon SD
    : Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19 [published online ahead of print Mar 30, 2020]. N Engl J Med doi:10.1056/NEJMsr2005760
  8. ↵
    1. Walsh M,
    2. Merkel PA,
    3. Peh CA,
    4. Szpirt WM,
    5. Puéchal X,
    6. Fujimoto S,
    7. Hawley CM,
    8. Khalidi N,
    9. Floßmann O,
    10. Wald R,
    11. Girard LP,
    12. Levin A,
    13. Gregorini G,
    14. Harper L,
    15. Clark WF,
    16. Pagnoux C,
    17. Specks U,
    18. Smyth L,
    19. Tesar V,
    20. Ito-Ihara T,
    21. de Zoysa JR,
    22. Szczeklik W,
    23. Flores-Suárez LF,
    24. Carette S,
    25. Guillevin L,
    26. Pusey CD,
    27. Casian AL,
    28. Brezina B,
    29. Mazzetti A,
    30. McAlear CA,
    31. Broadhurst E,
    32. Reidlinger D,
    33. Mehta S,
    34. Ives N,
    35. Jayne DRW
    ; PEXIVAS Investigators: Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382: 622–631, 2020pmid:32053298
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rauen T,
    2. Eitner F,
    3. Fitzner C,
    4. Sommerer C,
    5. Zeier M,
    6. Otte B,
    7. Panzer U,
    8. Peters H,
    9. Benck U,
    10. Mertens PR,
    11. Kuhlmann U,
    12. Witzke O,
    13. Gross O,
    14. Vielhauer V,
    15. Mann JF,
    16. Hilgers RD,
    17. Floege J
    ; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225–2236, 2015pmid:26630142
    OpenUrlCrossRefPubMed
  10. ↵
    1. Lv J,
    2. Zhang H,
    3. Wong MG,
    4. Jardine MJ,
    5. Hladunewich M,
    6. Jha V,
    7. Monaghan H,
    8. Zhao M,
    9. Barbour S,
    10. Reich H,
    11. Cattran D,
    12. Glassock R,
    13. Levin A,
    14. Wheeler D,
    15. Woodward M,
    16. Billot L,
    17. Chan TM,
    18. Liu ZH,
    19. Johnson DW,
    20. Cass A,
    21. Feehally J,
    22. Floege J,
    23. Remuzzi G,
    24. Wu Y,
    25. Agarwal R,
    26. Wang HY,
    27. Perkovic V
    ; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017pmid:28763548
    OpenUrlCrossRefPubMed
  11. ↵
    1. Fervenza FC,
    2. Appel GB,
    3. Barbour SJ,
    4. Rovin BH,
    5. Lafayette RA,
    6. Aslam N,
    7. Jefferson JA,
    8. Gipson PE,
    9. Rizk DV,
    10. Sedor JR,
    11. Simon JF,
    12. McCarthy ET,
    13. Brenchley P,
    14. Sethi S,
    15. Avila-Casado C,
    16. Beanlands H,
    17. Lieske JC,
    18. Philibert D,
    19. Li T,
    20. Thomas LF,
    21. Green DF,
    22. Juncos LA,
    23. Beara-Lasic L,
    24. Blumenthal SS,
    25. Sussman AN,
    26. Erickson SB,
    27. Hladunewich M,
    28. Canetta PA,
    29. Hebert LA,
    30. Leung N,
    31. Radhakrishnan J,
    32. Reich HN,
    33. Parikh SV,
    34. Gipson DS,
    35. Lee DK,
    36. da Costa BR,
    37. Jüni P,
    38. Cattran DC
    ; MENTOR Investigators: Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med 381: 36–46, 2019pmid:31269364
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 15 (6)
Clinical Journal of the American Society of Nephrology
Vol. 15, Issue 6
June 08, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
How COVID-19 Has Changed the Management of Glomerular Diseases
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How COVID-19 Has Changed the Management of Glomerular Diseases
Andrew S. Bomback, Pietro A. Canetta, Wooin Ahn, Syeda B. Ahmad, Jai Radhakrishnan, Gerald B. Appel
CJASN Jun 2020, 15 (6) 876-879; DOI: 10.2215/CJN.04530420

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
How COVID-19 Has Changed the Management of Glomerular Diseases
Andrew S. Bomback, Pietro A. Canetta, Wooin Ahn, Syeda B. Ahmad, Jai Radhakrishnan, Gerald B. Appel
CJASN Jun 2020, 15 (6) 876-879; DOI: 10.2215/CJN.04530420
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Reducing the Burden of CKD among Latinx
  • Social Determinants of Health in People with Kidney Disease
  • Personal Experiences of Patients in the Interaction of Culture and Kidney Disease
Show more Perspectives

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • glomerular disease
  • immunosuppression
  • COVID-19
  • severe acute respiratory syndrome coronavirus 2
  • kidney diseases

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire